158 related articles for article (PubMed ID: 33064345)
1. Real-life data on basal cell carcinoma treatment: Insights on clinicians' therapeutic choices from an institutional hospital registry.
Manoli SM; Moutsoudis A; Papageorgiou C; Lallas K; Rigas HM; Kyrmanidou E; Papadimitriou I; Paschou E; Spyridis I; Gkentsidi T; Sotiriou E; Vakirlis E; Ioannidis D; Apalla Z; Lallas A
Dermatol Ther; 2020 Nov; 33(6):e14414. PubMed ID: 33064345
[TBL] [Abstract][Full Text] [Related]
2. A retrospective comparative study of outcome with surgical excision and repair versus nonsurgical and ablative treatments for basal cell carcinoma.
Mahajan S; Kalaivani M; Sethuraman G; Khaitan BK; Verma KK; Gupta S
Indian J Dermatol Venereol Leprol; 2021; 87(3):348-356. PubMed ID: 33666033
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of multifocal pigmented basal cell carcinomas with the application of topical 5% imiquimod cream.
Plachouri KM; Balasis S; Mallioris AF; Koumoundourou D; Georgiou S
Dermatol Ther; 2018 Sep; 31(5):e12685. PubMed ID: 30133929
[TBL] [Abstract][Full Text] [Related]
4. Immunocryosurgery is a safe and feasible treatment for basal cell carcinoma and Bowen disease in renal transplant recipients.
Tsironi T; Gaitanis G; Pappas C; Koutlas V; Dounousi E; Bassukas ID
Dermatol Ther; 2022 May; 35(5):e15405. PubMed ID: 35194902
[TBL] [Abstract][Full Text] [Related]
5. The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers.
Gaitanis G; Zampeta A; Tsintzou P; Fillis G; Seretis K; Feldmeyer L; Bassukas I
Curr Oncol; 2022 Nov; 29(11):8475-8482. PubMed ID: 36354728
[TBL] [Abstract][Full Text] [Related]
6. Immunocryosurgery for non-superficial basal cell carcinomas ≤ 20 mm in maximal diameter: Five-year follow-up.
Gaitanis G; Bassukas ID
J Geriatr Oncol; 2019 May; 10(3):475-478. PubMed ID: 30219274
[TBL] [Abstract][Full Text] [Related]
7. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib.
Zargari O; Azimi SZ; Geranmayeh S
Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28631369
[TBL] [Abstract][Full Text] [Related]
8. Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application.
Gaitanis G; Nomikos K; Vava E; Alexopoulos EC; Bassukas ID
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1427-31. PubMed ID: 19555364
[TBL] [Abstract][Full Text] [Related]
9. Cryosurgery during Imiquimod (Immunocryosurgery) for Periocular Basal Cell Carcinomas: An Efficacious Minimally Invasive Treatment Alternative.
Gaitanis G; Kalogeropoulos CD; Bassukas ID
Dermatology; 2016; 232(1):17-21. PubMed ID: 26583773
[TBL] [Abstract][Full Text] [Related]
10. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma.
Vidal D; Matías-Guiu X; Alomar A
Clin Exp Dermatol; 2004 Sep; 29(5):518-25. PubMed ID: 15347339
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
12. New treatment modalities for basal cell carcinoma.
Stockfleth E; Sterry W
Recent Results Cancer Res; 2002; 160():259-68. PubMed ID: 12079222
[TBL] [Abstract][Full Text] [Related]
13. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.
Peris K; Fargnoli MC; Garbe C; Kaufmann R; Bastholt L; Seguin NB; Bataille V; Marmol VD; Dummer R; Harwood CA; Hauschild A; Höller C; Haedersdal M; Malvehy J; Middleton MR; Morton CA; Nagore E; Stratigos AJ; Szeimies RM; Tagliaferri L; Trakatelli M; Zalaudek I; Eggermont A; Grob JJ;
Eur J Cancer; 2019 Sep; 118():10-34. PubMed ID: 31288208
[TBL] [Abstract][Full Text] [Related]
15. Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.
Gaitanis G; Bassukas ID
Acta Derm Venereol; 2014 Jan; 94(1):38-44. PubMed ID: 23722308
[TBL] [Abstract][Full Text] [Related]
16. Emerging trends in the treatment of advanced basal cell carcinoma.
Migden MR; Chang ALS; Dirix L; Stratigos AJ; Lear JT
Cancer Treat Rev; 2018 Mar; 64():1-10. PubMed ID: 29407368
[TBL] [Abstract][Full Text] [Related]
17. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.
Ally MS; Aasi S; Wysong A; Teng C; Anderson E; Bailey-Healy I; Oro A; Kim J; Chang AL; Tang JY
J Am Acad Dermatol; 2014 Nov; 71(5):904-911.e1. PubMed ID: 24929884
[TBL] [Abstract][Full Text] [Related]
18. Interventions for basal cell carcinoma of the skin.
Bath-Hextall FJ; Perkins W; Bong J; Williams HC
Cochrane Database Syst Rev; 2007 Jan; (1):CD003412. PubMed ID: 17253489
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
20. Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study.
Gaitanis G; Alexopoulos EC; Bassukas ID
Eur J Dermatol; 2011; 21(6):952-8. PubMed ID: 21926038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]